Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Florian ScottéDavey DanielDaniel VaenaDennis SlaterHarry StaszewskiBruno FangLasika SeneviratneElaine YuRichard PriceTania SzadoCraig S MeyerAnuj ShahEsprit MaPublished in: Future oncology (London, England) (2023)
Aim: Biomarker testing detects actionable driver mutations to inform first-line treatment in advanced non-small-cell lung cancer (aNSCLC) and metastatic colorectal cancer (mCRC). This study evaluated biomarker testing in a nationwide database (NAT) versus the OneOncology (OneOnc) community network. Patients & methods: Patients with aNSCLC or mCRC with ≥1 biomarker test in a de-identified electronic health record-derived database were evaluated. OneOnc oncologists were surveyed. Results: Biomarker testing rates were high and comparable between OneOnc and NAT; next-generation sequencing (NGS) rates were higher at OneOnc. Patients with NGS versus other biomarker testing were more likely to receive targeted treatment. Operational challenges and insufficient tissue were barriers to NGS testing. Conclusion: Community cancer centers delivered personalized healthcare through biomarker testing.
Keyphrases
- advanced non small cell lung cancer
- healthcare
- metastatic colorectal cancer
- electronic health record
- mental health
- end stage renal disease
- emergency department
- ejection fraction
- squamous cell carcinoma
- cross sectional
- chronic kidney disease
- young adults
- newly diagnosed
- gene expression
- dna methylation
- peritoneal dialysis
- palliative care
- prognostic factors
- patient reported outcomes